Chronic lymphocytic Leukemia Venetoclax in the First-Line with significant Survival Benefit

被引：0
|
作者：
Warpakowski, Andrea
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN COLOMBIA
    Ordonez, J.
    Quitian, D.
    VALUE IN HEALTH, 2021, 24 : S29 - S29
  • [32] First-line treatments for chronic lymphocytic leukemia: Analysis of 7 trials based on the restricted mean survival time
    Bartoli, Laura
    Ferracane, Elisa
    Trippoli, Sabrina
    Messori, Andrea
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (04) : 322 - 327
  • [33] Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves
    Alrawashdh, Neda
    Persky, Daniel O.
    McBride, Ali
    Sweasy, Joann
    Erstad, Brian
    Abraham, Ivo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : E820 - E831
  • [34] The impact of prognostic markers on first-line treatment decisions in chronic lymphocytic leukemia
    Langerbeins, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 92 - 92
  • [35] Oral fludarabine phosphate as first-line treatment of chronic lymphocytic leukemia.
    Rossi, JF
    Van Hoof, A
    De Bock, R
    Johnson, SA
    Bron, D
    Foussard, C
    Lister, TA
    Berthou, C
    Kramer, MHH
    Littlewood, TJ
    Marcus, RE
    Deconinck, E
    Montillo, M
    Tollerfield, SM
    BLOOD, 2002, 100 (11) : 384A - 385A
  • [36] Cost burden of first-line treatment failure in patients with chronic lymphocytic leukemia
    Lafeuille, Marie-Helene
    Wang, Song
    Lefebvre, Patrick
    Senbetta, Mekre
    Emond, Bruno
    Romdhani, Hela
    LEUKEMIA & LYMPHOMA, 2017, 58 : 99 - 100
  • [37] Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Ferrajoli, Alessandra
    Yilmaz, Musa
    Thompson, Philip A.
    Konopleva, Marina
    Green, Michael R.
    Sampath, Deepa
    Neelapu, Sattva S.
    Takahashi, Koichi
    Masarova, Lucia
    Burger, Jan A.
    Kanagal-Shamanna, Rashmi
    Khoury, Joseph D.
    Garg, Naveen
    Su, Xiaoping
    Wang, Xuemei
    Patel, Hinalben
    Ayala, Ana
    Kantarjian, Hagop
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2021, 138
  • [38] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Sasaki, Koji
    Kadia, Tapan M.
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Wei, Chongjuan
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2021, 138 : 3720 - +
  • [39] Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 14 - 15
  • [40] Long-term efficacy of ibrutinib-venetoclax for first-line treatment in chronic lymphocytic leukaemia
    Fink, Anna
    LANCET ONCOLOGY, 2023, 24 (12): : 1294 - 1295
12345